# Adaptive Genetic Research Domain Categories (DOMAINS.md)

## Overview
This document categorizes genetic research domains for the adaptive literature review skill that adjusts its approach based on three distinct review archetypes:
- **Type A (Paradigm/Ethics)**: Policy, Ethics, New Standards
- **Type B (Clinical Management)**: Screening, Guidelines, Practice
- **Type C (Precision Mechanism)**: Genetics, Rare Disease, Targets

Each domain represents a distinct area of genetic research with specific methodologies, technologies, and applications appropriate to the selected review type.

## Domain 1: Rare Disease Genetics

### Type A Focus: Policy and Ethical Implications
- **Newborn Screening Policy**: Ethical considerations for expanding screening panels
- **Genetic Privacy**: Legal frameworks and privacy protection policies
- **Insurance Coverage**: Access to genetic testing and treatment policies
- **International Harmonization**: Global standards for rare disease genetics

#### Key Metrics for Type A
- Policy adoption rates
- Privacy protection indices
- Insurance coverage disparities
- Cross-border regulatory alignment

#### Literature Keywords for Type A
- "genetic discrimination", "insurance policy", "privacy legislation", "international harmonization"

### Type B Focus: Clinical Management and Implementation
- **Diagnostic Pathways**: Clinical algorithms for rare disease diagnosis
- **Screening Programs**: Implementation of genetic screening
- **Care Coordination**: Multidisciplinary care models
- **Outcome Optimization**: Clinical management protocols

#### Key Metrics for Type B
- Diagnostic yield (%)
- Time to diagnosis (days/months)
- Care coordination scores
- Clinical outcome improvements

#### Literature Keywords for Type B
- "clinical pathway", "screening protocol", "care coordination", "clinical outcomes"

### Type C Focus: Molecular Mechanisms and Precision Medicine
- **Molecular Pathogenesis**: Mechanisms underlying rare genetic conditions
- **Genotype-Phenotype Correlations**: Relationships between genetic variants and clinical features
- **Functional Annotation**: Biological significance of genetic variants
- **Targeted Therapies**: Mechanism-based therapeutic approaches

#### Key Metrics for Type C
- Variant pathogenicity scores
- Genotype-phenotype correlation strength
- Functional impact measures
- Treatment response rates

#### Literature Keywords for Type C
- "molecular mechanism", "genotype-phenotype", "functional analysis", "targeted therapy"

## Domain 2: Population Genetics and Genomics

### Type A Focus: Population-Level Policy Implications
- **Population Screening Ethics**: Ethical considerations for large-scale genetic screening
- **Data Sharing Policies**: International frameworks for genomic data sharing
- **Genetic Discrimination**: Policy responses to prevent discrimination
- **Global Health Equity**: Access to genetic services across populations

#### Key Metrics for Type A
- Data sharing compliance rates
- Discrimination incidence rates
- Access equity indices
- Policy harmonization scores

#### Literature Keywords for Type A
- "population screening ethics", "data governance", "global health equity", "discrimination policy"

### Type B Focus: Clinical Implementation of Population Findings
- **Risk Stratification Programs**: Implementing polygenic risk scores in clinics
- **Ancestry-Based Medicine**: Clinical applications of genetic ancestry
- **Population Screening**: Translation of research findings to clinical practice
- **Quality Assurance**: Standards for population-level genetic testing

#### Key Metrics for Type B
- Risk stratification accuracy
- Clinical implementation rates
- Screening uptake (%)
- Quality assurance scores

#### Literature Keywords for Type B
- "risk stratification", "clinical implementation", "screening uptake", "quality standards"

### Type C Focus: Population-Scale Molecular Insights
- **Natural Selection**: Molecular signatures of evolutionary pressures
- **Population-Specific Variants**: Functional significance of population-differentiated variants
- **Admixture Mapping**: Molecular insights from population mixing
- **Demographic History**: Molecular consequences of population history

#### Key Metrics for Type C
- Selection coefficient estimates
- Functional impact of population variants
- Admixture mapping resolution
- Demographic parameter estimates

#### Literature Keywords for Type C
- "selection pressure", "functional variants", "admixture mapping", "demographic inference"

## Domain 3: Functional Genomics

### Type A Focus: Functional Genomics Policy and Ethics
- **CRISPR Regulation**: Policy frameworks for functional genomics applications
- **Data Interpretation Standards**: Ethical guidelines for functional data
- **International Collaboration**: Governance of functional genomics research
- **Public Engagement**: Communicating functional genomics findings

#### Key Metrics for Type A
- Regulatory compliance rates
- Data interpretation consistency
- Collaboration agreement rates
- Public understanding scores

#### Literature Keywords for Type A
- "CRISPR regulation", "data standards", "international governance", "public engagement"

### Type B Focus: Clinical Application of Functional Insights
- **Functional Biomarkers**: Clinical utility of functional genomic markers
- **Treatment Selection**: Using functional data for therapeutic choices
- **Monitoring Protocols**: Functional measures for treatment monitoring
- **Clinical Decision Making**: Integrating functional data into care

#### Key Metrics for Type B
- Biomarker clinical utility scores
- Treatment selection accuracy
- Monitoring protocol adherence
- Clinical decision improvement rates

#### Literature Keywords for Type B
- "clinical utility", "treatment selection", "monitoring protocols", "clinical decision support"

### Type C Focus: Molecular Mechanisms and Pathways
- **Pathway Analysis**: Detailed characterization of molecular pathways
- **Regulatory Networks**: Understanding gene regulation mechanisms
- **Protein Function**: Molecular basis of protein dysfunction
- **Cellular Models**: Mechanistic insights from cellular systems

#### Key Metrics for Type C
- Pathway enrichment scores
- Network connectivity measures
- Protein activity changes
- Model system validation rates

#### Literature Keywords for Type C
- "pathway analysis", "regulatory networks", "protein function", "cellular models"

## Domain 4: Gene Therapy and Editing

### Type A Focus: Gene Therapy Policy and Ethics
- **Germline Editing Ethics**: Policy frameworks for heritable genome editing
- **Commercial Access**: Equity in access to gene therapies
- **International Harmonization**: Regulatory convergence for gene therapy
- **Societal Readiness**: Public acceptance of gene editing technologies

#### Key Metrics for Type A
- Regulatory approval timelines
- Access equity measures
- Harmonization indices
- Public acceptance scores

#### Literature Keywords for Type A
- "germline editing", "access equity", "regulatory harmonization", "public acceptance"

### Type B Focus: Clinical Implementation of Gene Therapies
- **Delivery Protocols**: Clinical implementation of gene therapy delivery
- **Patient Selection**: Criteria for gene therapy eligibility
- **Monitoring Strategies**: Post-treatment surveillance protocols
- **Outcome Assessment**: Clinical endpoints for gene therapy

#### Key Metrics for Type B
- Delivery success rates
- Patient selection accuracy
- Monitoring protocol compliance
- Clinical outcome achievement

#### Literature Keywords for Type B
- "delivery protocols", "patient selection", "monitoring strategies", "clinical outcomes"

### Type C Focus: Molecular Basis of Gene Therapy
- **Vector Biology**: Molecular mechanisms of vector function
- **Editing Precision**: Molecular fidelity of gene editing
- **Cellular Responses**: Molecular basis of therapeutic effects
- **Resistance Mechanisms**: Molecular basis of therapy failure

#### Key Metrics for Type C
- Vector transduction efficiency
- Editing precision rates
- Cellular response signatures
- Resistance frequency

#### Literature Keywords for Type C
- "vector biology", "editing precision", "cellular response", "resistance mechanisms"

## Domain 5: Pharmacogenomics

### Type A Focus: Pharmacogenomics Policy and Implementation
- **Testing Mandates**: Policy requirements for pharmacogenomic testing
- **Data Integration**: Privacy and standards for pharmacogenomic data
- **Equity in Implementation**: Policy approaches to ensure equitable access
- **Regulatory Frameworks**: Oversight of pharmacogenomic applications

#### Key Metrics for Type A
- Testing mandate compliance
- Data integration success rates
- Access equity measures
- Regulatory approval efficiency

#### Literature Keywords for Type A
- "testing mandates", "data integration", "access equity", "regulatory oversight"

### Type B Focus: Clinical Implementation of Pharmacogenomics
- **Clinical Decision Support**: Integration of PGx data into clinical workflows
- **Prescribing Guidelines**: Evidence-based PGx-informed prescribing
- **Implementation Barriers**: Clinical obstacles to PGx adoption
- **Outcome Improvements**: Clinical benefits of PGx-guided therapy

#### Key Metrics for Type B
- Decision support adoption rates
- Guideline adherence scores
- Implementation barrier reduction
- Clinical outcome improvements

#### Literature Keywords for Type B
- "decision support", "prescribing guidelines", "implementation barriers", "clinical outcomes"

### Type C Focus: Molecular Basis of Drug-Gene Interactions
- **Metabolic Pathways**: Molecular mechanisms of drug metabolism
- **Protein Function**: Impact of genetic variants on protein-drug interactions
- **Systems Pharmacology**: Network-level effects of genetic variation
- **Mechanistic Insights**: Molecular basis of variable drug responses

#### Key Metrics for Type C
- Metabolic pathway efficiency
- Protein-drug binding affinity
- Network perturbation scores
- Mechanistic explanation rates

#### Literature Keywords for Type C
- "metabolic pathways", "protein-drug interactions", "systems pharmacology", "mechanistic insights"

## Domain 6: Cancer Genomics

### Type A Focus: Cancer Genomics Policy and Ethics
- **Tumor Profiling Ethics**: Ethical considerations for comprehensive tumor profiling
- **Data Sharing**: Policies for sharing cancer genomic data
- **Access to Testing**: Equity in access to cancer genomic testing
- **Incidental Findings**: Policy for handling germline findings in cancer

#### Key Metrics for Type A
- Data sharing participation rates
- Testing access equity measures
- Incidental finding disclosure rates
- Policy implementation success

#### Literature Keywords for Type A
- "tumor profiling ethics", "data sharing", "testing access", "incidental findings"

### Type B Focus: Clinical Implementation of Cancer Genomics
- **Tumor Board Integration**: Incorporating genomic data into treatment decisions
- **Liquid Biopsy Implementation**: Clinical use of circulating tumor DNA
- **Treatment Matching**: Genomic-guided therapy selection
- **Monitoring Protocols**: Genomic-guided treatment monitoring

#### Key Metrics for Type B
- Tumor board utilization rates
- Liquid biopsy clinical utility
- Treatment matching success
- Monitoring protocol effectiveness

#### Literature Keywords for Type B
- "tumor board", "liquid biopsy", "treatment matching", "monitoring protocols"

### Type C Focus: Molecular Oncology
- **Tumor Evolution**: Molecular mechanisms of cancer evolution
- **Resistance Mechanisms**: Molecular basis of therapy resistance
- **Immune Interactions**: Molecular basis of tumor-immune interactions
- **Metastasis**: Molecular mechanisms of cancer spread

#### Key Metrics for Type C
- Evolutionary rate estimates
- Resistance mechanism identification
- Immune infiltration scores
- Metastasis pathway activity

#### Literature Keywords for Type C
- "tumor evolution", "resistance mechanisms", "immune interactions", "metastasis"

## Adaptive Literature Organization Framework

### For Type A Reviews:
1. Organize by policy domain (regulatory, ethical, societal)
2. Focus on stakeholder perspectives
3. Emphasize benefit-risk analysis
4. Include international comparisons

### For Type B Reviews:
1. Organize by clinical application (screening, diagnosis, treatment)
2. Focus on implementation pathways
3. Emphasize outcome measures
4. Include barrier analysis

### For Type C Reviews:
1. Organize by molecular mechanism or pathway
2. Focus on genotype-phenotype relationships
3. Emphasize mechanistic insights
4. Include case-level synthesis

This framework allows for adaptive organization while maintaining scientific rigor and comprehensive coverage appropriate to the selected review type.